Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Alifano, Marco ^a,b   Mansuet Lupo, Audrey ^a,b,c,d   Lococo, Filippo ^e   Roche, Nicolas ^a,b   Bobbio, Antonio ^a   Canny, Emelyne ^a   Schussler, Olivier ^a   Dermine, Hervé ^e   Régnard, Jean François ^a,b   Burroni, Barbara ^a   Goc, Jérémy ^b,c,d   Biton, Jérôme ^b,c,d   Ouakrim, Hanane ^b,c,d   Cremer, Isabelle ^b,c,d   Dieu Nosjean, Marie Caroline ^b,c,d   Damotte, Diane ^a,b,c,d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PREALBUMIN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CASE STUDY; CD8+ T LYMPHOCYTE; CELL DENSITY; CONTROLLED STUDY; DENDRITIC CELL; DISEASE CLASSIFICATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; KARNOFSKY PERFORMANCE STATUS; LOBECTOMY; LONG TERM SURVIVAL; LUNG ADENOCARCINOMA; LUNG RESECTION; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SMOKING; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC INFLAMMATION; TUMOR IMMUNE MICROENVIRONMENT; TUMOR MICROENVIRONMENT; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOLOGY; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; SURVIVAL;

C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CD8-POSITIVE T-LYMPHOCYTES; KARNOFSKY PERFORMANCE STATUS; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NUTRITIONAL STATUS; PREALBUMIN; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 84907204682     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106914     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Youlden DR, Cramb SM, Baade PD (2008) The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 3(8):819-831.
3. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, et al. (2011) Non-small-cell lung cancer. Lancet 378(9804):1727-40.
4. Custodio AB, González-Larriba JL, Bobokova J, Calles A, Alvarez R, et al. (2009) Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. J Thorac Oncol 4(7):891-910.
5. Simon GR (2008) Individualizing chemotherapy for non-small cell lung cancer (NSCLC) in the adjuvant and advanced setting: current status and future directions. Curr Treat Options Oncol 9(4-6):300-12.
6. Wakelee HA, Schiller JH, Gandara DR (2006) Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial. Clin Lung Cancer 8(1):18-21.
7. McMillan DC (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12(3):223-6.
8. Balkwill F, Mantovani A (2010) Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 87(4):401-6.
9. Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298-306
10. Lazennec G, Richmond A (2010) Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 16(3):133-44.
11. Shiels MS, Pfeiffer RM, Hildesheim A, Engels EA, Kemp TJ, et al. (2013) Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst 105(24):1871-80.
12. Allin KH, Bojesen SE, Nordestgaard BG (2009) Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 27(13):2217-2224.
13. Koch A, Fohlin H, Sörenson S (2009) Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol 4(3):326-32.
14. Alifano M, Falcoz PE, Seegers V, Roche N, Schussler O, et al. (2011) Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg 142(5):1161-7.
15. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, et al. (2008) Long-term survival for patients with non-small-cell lung cancer with intratu-moral lymphoid structures. J Clin Oncol. 26(27):4410-7.
16. Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, et al. (2013). Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res. 19(15):4079-91.
17. Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, et al. (2014) Dendritic cells in tumor-associated tertiary lymphoid structures license the positive prognostic value of tumor-infiltrating CD8+ T cells. Cancer Res 74(3):705-15.
18. Barnes PJ, Celli BR (2009) Systemic manifestations and comorbidities of COPD. Eur Respir J 33(5):1165-85.
19. Tewari N, Martin-Ucar AE, Black E, Beggs L, Beggs FD, et al. (2007) Nutritional status affects long term survival after lobectomy for lung cancer. Lung Cancer 57(3):389-94.
20. Kawai H, Ota H (2012) Low perioperative serum prealbumin predicts early recurrence after curative pulmonary resection for non-small-cell lung cancer. World J Surg 36(12):2853-7.
21. Schussler O, Alifano M, Dermine H, Strano S, Casetta A, et al. (2006) Postoperative pneumonia after major lung resection. Am J Respir Crit Care Med 173(10):1161-9.
22. Sobin LH, Gospodrowicz MK, Wittekind CH (2010) International Union against Cancer: TNM Classification of Malignant Tumours, 7th edition. New York: Wiley-Blackwell.
23. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, et al. (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6(2):244-85
24. Mansuet-Lupo A, Bobbio A, Blons H, Becht E, Ouakrim H, et al. (2014) The new histological classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. Chest. Mar 27. doi: 10.1378/chest.13-2499. [Epub ahead of print]
25. Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest. 111(12):1805-12.
26. Haura EB, Livingston S, Coppola D (2006) Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer. Clin Lung Cancer 2006 7(4):273-5.
27. Niiya M, Niiya K, Kiguchi T, Shibakura M, Asaumi N, et al. (2003) Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells. Cancer Chemother Pharmacol 52(5):391-398.
28. Fridman WH, Galon J, Dieu-Nosjean MC, Cremer I, Fisson S, et al. (2011) Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol 344: 1-24.
29. Jafri SH, Shi R, Mills G (2013) Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer 13: 158. doi: 10.1186/1471-2407-13-158.
30. Chandra RK (1997) Nutrtion and the immune system: an introduction. Am J Clin Nutr 66(2):460S-463S.
31. Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, et al. (2007) HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci Sep;98(9):1424-30. Epub 2007 Jul 23